Revolution Medicines starts Phase 3 trial of RASONQUE-zoldonrasib combo in first-line metastatic RAS G12D pancreatic cancer
RVMD•Revolution Medicines began dosing patients in a global Phase 3 trial testing daraxonrasib with zoldonrasib in first-line metastatic RAS G12D pancreatic cancer.
1. Phase 3 trial begins
Revolution Medicines began dosing patients in a global Phase 3 trial testing daraxonrasib with zoldonrasib in first-line metastatic RAS G12D pancreatic cancer. The study aims to determine whether the combination can outperform standard chemotherapy; earlier results in previously treated metastatic disease showed antitumor activity with manageable safety.
